martes, 6 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 23, 2026

AS-i Harju Elekter Group majandustulemused, 1-3/2026

View original at globenewswire.com
“Perioodi puhaskasum 192 [EUR'000] ... 2026 (Q1)”
Verbatim excerpt from the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Selling expenses grew 45.2% to 1.9 million EUR, driven by growth in marketing and sales services to support market activity, including participation in international trade fairs to strengthen visibility and showcase HECON EVO and Elektra Sense developments

    60% confidence
  • Middle East geopolitical tensions affect Harju Elekter primarily indirectly through global supply chains, logistics, and input prices; instability in international transport channels extends delivery times and raises freight costs

    60% confidence
  • Q1 2026 was considerably more difficult than expected and results did not meet expectations; the primary cause was supply chain disruptions that delayed deliveries and pushed order fulfillment to subsequent periods

    60% confidence
  • Uneven material flow disrupts planned work organisation, causes temporary stoppages, and loads production floor space, making resource management and production planning more complex than usual

    60% confidence
  • Both Estonian and Swedish unit order books are above average; a significant portion of pending orders is expected to materialize as revenue in the current financial year

    60% confidence
  • The company approaches the full year 2026 with moderate optimism but caution, as there are signs of a possible new crisis

    60% confidence
  • Material and component price increases will add to already long delivery times in the near future; first signals and new price lists have been received from suppliers; positive P&L impact expected with 1–2 quarter lag via framework contract indexation

    60% confidence
  • Rapid cost reduction is not possible without risking the inability to respond quickly enough to growing demand; retaining competency, team readiness, and capacity to respond when peak season arrives are strategically critical

    60% confidence
  • No order cancellations have occurred to date, but customer behaviour shows caution

    60% confidence
  • Lithuania unit's persistently low sales and resulting high idle production capacity indicate market challenges and the need for more effective sales organisation

    60% confidence
  • The majority of Estonian, Swedish, and Finnish unit results will materialize in Q2 and Q3, when substation deliveries to framework contract customers begin

    60% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,985
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,985 hechos verificados con la fuente5,351 documentos fuente archivados
Consulta estos datos → isubstrate.com